Want to see AU:TLX full AI Analyst Report?
TLX Stock Chart & Stats
AU$14.64
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$14.64
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$8.26 - AU$23.50
Previous CloseN/A
Volume456.62K
Average Volume (3M)2.08M
Market Cap
AU$5.20B
Enterprise ValueAU$4.28K
Total Cash (Recent Filing)AU$212.74M
Total Debt (Recent Filing)AU$699.77M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 20, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding339,784,300
10 Day Avg. Volume1,267,773
30 Day Avg. Volume2,083,872
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.23Price Target Upside72.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.04
Revenue Forecast (FY)AU$967.94M
Bulls Say, Bears Say
Bulls Say
Sustained High Revenue GrowthMulti-year, double-digit top-line growth demonstrates a scalable commercial model and accelerating market adoption. Continued guidance for ~20%+ growth supports durable demand, enabling reinvestment and capacity expansion that underpin longer-term earnings potential and competitive positioning.
High-margin Precision Medicine FranchiseA concentrated, high-margin core business provides durable cash generation and margin resilience. Precision Medicine's outsized contribution to gross margin shows product economics and pricing power that can fund R&D and international rollouts, stabilizing profitability as scale increases.
Integrated Manufacturing And Commercial Footprint (RLS)Owning manufacturing and distribution improves supply reliability for time-sensitive radiopharmaceuticals and supports margin capture. Positive EBITDA from RLS and full-year contribution in 2026 improve unit economics and reduce dependence on third parties, strengthening long-term commercial durability.
Bears Say
Rising Leverage And Higher Debt LoadA growing debt burden reduces financial flexibility and raises refinancing risk, especially for a business reinvesting heavily. Elevated leverage constrains the firm's ability to withstand regulatory or reimbursement delays and increases interest cost sensitivity, impacting sustained investment in growth.
Weakened Cash Generation / FCF ReversalA reversal to negative operating and free cash flow signals deteriorating cash conversion and raises funding needs. Persistent negative FCF would force external financing or cuts to R&D/commercial spend, threatening the self-funding strategy and slowing long-term pipeline progression.
Regulatory Setbacks And Resubmission RiskDelays or additional regulatory hurdles for key candidates create binary execution risk that can defer revenue diversification and expected therapeutic upside. Dependence on successful resubmissions makes medium-term growth and margin expansion contingent on regulatory timing and capability improvements.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$23.50 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$5.20B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 28 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of AU$0.057 by -AU$0.074.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.03.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,784,300 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of AU$0.057. Following the earnings report the stock price went up 14.239%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.23 (72.36% Upside)
AU$25.23 (72.36% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLX Stock 12 Month Forecast
Average Price Target
AU$25.23
▲(72.36% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―